Effects of PDCA cycle management on patients with acute myelocytic leukemia receiving decitabine combined with low dose idarubicin and cytarabine

International Journal of Industrial Chemistry

دوره 13، شماره 1، خرداد 2022، صفحه 1-11   

نوع مقاله: research article

شناسه دیجیتال (DOI): 10.47176/IJIC.13.1.1

نویسندگان

Bingling Yin^* ؛ Lei Geng

Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China

چکیده

Acute myeloid leukemia (AML) is a hematologic neoplasm that occurs in adults, especially in the elderly. This study was performed to investigate the impact of a plan, do, check, act (PDCA)-based care management model on the clinical outcomes and quality of life of patients with AML receiving the decitabine (DCA) regimen in combination with low dose idarubicin + cytarabine (IA). Eighty-four patients with AML were enrolled in this study. Among them, 42 patients in the control group adopted DCA co-IA regiment and routine nursing, the other 42 cases in the observation group underwent the DCA co-IA regiment and PDCA nursing management. The immune function, hematopoietic function, clinical efficacy, quality of life, prognosis, and occurrence of adverse reactions were observed and compared between the two groups. After care, the observation group had higher CD4+ (P<0.0001), CD4+/CD8+ (P=0.0022), HGB (P<0.0001) and PLT (P<0.0001) level, clinical treatment efficiency (P=0.0189), and nursing satisfaction (P=0.0066) in relation to the control group. However, the CD8+ (P<0.0001), WBC (P<0.0001), incidence of adverse reactions (P=0.0189, P=0.0347 and P=0.0206), SAS score (P<0.001), SDS score (P<0.001), and QLI score (P<0.01) were lower in the observation group than those in the control group. In summary, the implementation of PDCA nursing management for AML patients undergoing DCA + IA chemotherapy treatment can improve patients’ immune function, clinical efficacy, quality of life and psychological status, reduce the occurrence of complications, and improve nursing satisfaction, which has clinical promotion value.

کلیدواژه‌ها

Acute myelocytic leukemia؛ PDCA management model؛ Immune function؛ Hematopoietic function